Impact of mobility on structure-based drug design for the MMPs

被引:55
作者
Moy, FJ
Chanda, PK
Chen, J
Cosmi, S
Edris, W
Levin, JI
Rush, TS
Wilhelm, J
Powers, R
机构
[1] Wyeth Res, Dept Biol Chem, Cambridge, MA 02140 USA
[2] Wyeth Res, Chem Sci, Pearl River, NY 10965 USA
关键词
D O I
10.1021/ja027391x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Structure-based approaches for drug design generally do not incorporate solvent effects and dynamic information to predict inhibitor-binding affinity because of practical limitations. The matrix metalloproteinases (MMPs) have previously been demonstrated to exhibit significant mobility in their active sites. This dynamic characteristic significantly complicates the drug design process based on static structures, which was clearly observed for a class of hydroxamic acids containing a butynyl moiety. Compound 1 was expected to be selective against MMP-1 based on predicted steric clashes between the butynyl P1′ group and the S1′ pocket, but the observation of complex inhibitor dynamics in the NMR structure of MMP-1:1 provides an explanation for the low nanomolar binding to MMP-1. Copyright © 2002 American Chemical Society.
引用
收藏
页码:12658 / 12659
页数:2
相关论文
共 18 条
[1]  
Baker BM, 1998, METHOD ENZYMOL, V295, P294
[2]   Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design [J].
Chen, JM ;
Nelson, FC ;
Levin, JI ;
Mobilio, D ;
Moy, FJ ;
Nilakantan, R ;
Zask, A ;
Powers, R .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (40) :9648-9654
[3]   Recent advances in structure-based rational drug design [J].
Gane, PJ ;
Dean, PM .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2000, 10 (04) :401-404
[4]  
GUBERNATOR K, 1998, METH PRIN MED CHEM, V6, P15
[5]   Computational approaches to structure-based ligand design [J].
Joseph-McCarthy, D .
PHARMACOLOGY & THERAPEUTICS, 1999, 84 (02) :179-191
[6]  
Kubinyi H, 1998, Curr Opin Drug Discov Devel, V1, P4
[7]  
Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217
[8]   Structure-based design of a new class of anti-inflammatory drugs:: secretory phospholipase A2 inhibitors, SPI [J].
Mihelich, ED ;
Schevitz, RW .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 1999, 1441 (2-3) :223-228
[9]   High-resolution solution structure of the inhibitor-free catalytic fragment of human fibroblast collagenase determined by multidimensional NMR [J].
Moy, FJ ;
Chanda, PK ;
Cosmi, S ;
Pisano, MR ;
Urbano, C ;
Wilhelm, J ;
Powers, R .
BIOCHEMISTRY, 1998, 37 (06) :1495-1504
[10]   Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase [J].
Moy, FJ ;
Pisano, MR ;
Chanda, PK ;
Urbano, C ;
Killar, LM ;
Sung, ML ;
Powers, R .
JOURNAL OF BIOMOLECULAR NMR, 1997, 10 (01) :9-19